Search Results - "Morrow, Nadya M"

  • Showing 1 - 13 results of 13
Refine Results
  1. 1
  2. 2

    The citrus flavonoid nobiletin confers protection from metabolic dysregulation in high-fat-fed mice independent of AMPK[S] by Morrow, Nadya M., Burke, Amy C., Samsoondar, Joshua P., Seigel, Kyle E., Wang, Andrew, Telford, Dawn E., Sutherland, Brian G., O'Dwyer, Conor, Steinberg, Gregory R., Fullerton, Morgan D., Huff, Murray W.

    Published in Journal of lipid research (01-03-2020)
    “…Obesity, dyslipidemia, and insulin resistance, the increasingly common metabolic syndrome, are risk factors for CVD and type 2 diabetes that warrant novel…”
    Get full text
    Journal Article
  3. 3

    Understanding Dietary Intervention-Mediated Epigenetic Modifications in Metabolic Diseases by Asif, Shaza, Morrow, Nadya M, Mulvihill, Erin E, Kim, Kyoung-Han

    Published in Frontiers in genetics (15-10-2020)
    “…The global prevalence of metabolic disorders, such as obesity, diabetes and fatty liver disease, is dramatically increasing. Both genetic and environmental…”
    Get full text
    Journal Article
  4. 4

    Distinct Identity of GLP-1R, GLP-2R, and GIPR Expressing Cells and Signaling Circuits Within the Gastrointestinal Tract by Morrow, Nadya M., Hanson, Antonio A., Mulvihill, Erin E.

    “…Enteroendocrine cells directly integrate signals of nutrient content within the gut lumen with distant hormonal responses and nutrient disposal via the…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7

    Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut by Morrow, Nadya M., Morissette, Arianne, Mulvihill, Erin E.

    Published in Peptides (New York, N.Y. : 1980) (01-06-2024)
    “…Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are peptide hormones produced by enteroendocrine cells in the small…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12

    GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms by Mullur, Neerav, Morissette, Arianne, Morrow, Nadya M, Mulvihill, Erin E

    Published in Journal of endocrinology (01-10-2024)
    “…Cardiovascular outcome trials (CVOTs) in people living with type 2 diabetes mellitus and obesity have confirmed the cardiovascular benefits of glucagon-like…”
    Get more information
    Journal Article
  13. 13